BioCardia takes a new and comprehensive approach to heart failure

We are developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases to improve the lives of patients from unmet medical needs.

Read More

Discover us

Financials & Filings

Review our corporate financial reports and SEC filings

Press Releases

Read about our latest company milestones

Clinical Trials

Complete Questionnaire to find out if you or a loved one qulifies for our CardiAMP Heart Failure Study

Product Pipeline

Learn about our product development programs and obtain an at-a-glance view of their current status

Products

Helix Biotherapeutic Delivery System

AVANCE Steerable Introducer

News

06 Dec

Fierce Biotech

BioCardia's off-the-shelf cell therapy for heart failure to enter first-in-human study
Read More
01 Dec

Empowered Patient Podcast

Optimizing Autologous Cell Therapy to Treat Cardiovascular Disease with Dr. Peter Altman
Read More
29 Oct

UW Health

UW Health Treats First Patient in U.S. with Investigational Cell Therapy for Heart Disease
Read More
29 Oct

Greenbay CBS

Neenah musician, educator pursues dream after being first in the world to undergo ‘Investigational Cell Therapy’
Read More
29 Oct

WBay.com

Neenah man gets new lease on life after trial heart procedure
Read More
04 Mar

Henry Ford Health System

Henry Ford Health System Studies Novel Cell Therapy Aimed at Improving Heart Failure Symptoms
Read More
08 Feb

Cell & Gene

Inside BioCardia's CardiAMP Cell Therapy
Read More
15 Sep

BioTuesdays

BioCardia developing autologous and allogenic cardiovascular cell therapies
Read More
03 Aug

Pharmaceutical Technology

BioCardia’s novel CardiAMP stem cell therapy closer to approval in heart failure
Read More

press releases

29 Nov
2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval
16 Nov
2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
14 Nov
2023 BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
08 Nov
2023 BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results
01 Nov
2023 BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023
11 Oct
2023 BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS